Semax: Human Brain Imaging, No Cognitive Outcome

Semax is sold as a nootropic, and unlike most compounds in that market it has been studied in people. Fifty-two healthy participants were given semax, selank or placebo and had resting-state fMRI three times: before the injection, then five and twenty minutes after it. Differences in functional connectivity were found, involving the right amygdala and temporal regions.^[1] What decides its meaning is the endpoint. The study measured connectivity between brain regions. It did not measure memory, attention, or any task anybody performed.

What was actually measured

The design is careful. Regions of interest were predefined rather than fished for: the amygdala, central to anxiety regulation, and the dorsolateral prefrontal cortex, central to executive function including working memory, in both hemispheres. There was a placebo arm. Scans were repeated at fixed intervals.^[1]

The findings were between-group and between-condition differences in functional connectivity between the right amygdala and a region spanning the fusiform, inferior and middle temporal and parahippocampal gyri. Put plainly, the correlation in activity between two parts of the brain changed after injection.

The rest of the evidence is rodents

Semax is an analog of a fragment of ACTH, and the mechanistic work behind it is animal neurochemistry. In rodents, it activates dopaminergic and serotoninergic brain systems.^[2] That is a coherent basis for a hypothesis about mood and cognition, but it is animal work and says nothing yet about people.

Put the two together and the shape is familiar from across this market: a plausible mechanism in animals, a measurable signal in a human imaging study, and no trial testing whether anyone functions better. The missing study would be an ordinary one: a randomized trial with a cognitive endpoint.

The evidence is rodent neurochemistry and one imaging study. No trial has tested whether anyone functions better.

The same caveat as its sibling

Semax shares its evidence base, and much of its author group, with selank. Both compounds sit almost entirely within one national research literature, produced largely around the institute that developed them, without independent replication elsewhere. The weakness lies in how the evidence is structured, not in which country produced it, and it applies to both.

• Semax is not an approved medicine in the United States. Most of it is sold as a research chemical, without identity, purity or dose guarantees. How semax compares with selank under the October 2026 HHS policy is in Semax vs Selank.
• Under an interim policy dated October 28, 2026, HHS does not plan to pursue state-licensed 503A pharmacies that compound semax free base as an intranasal product only, on a patient-specific prescription and under strict testing and labeling conditions. The policy's device condition names only an FDA-cleared syringe, so it leaves open which nasal device may be used. It is not an approval, and it does nothing to the evidence described here.^[3]
• The human study measured brain connectivity in healthy volunteers, with no cognitive or symptom endpoint.
• The mechanistic work is in rodents.
• If you are seeking help with concentration, memory or mood, have those problems assessed properly. Several have treatable causes, and none of them is diagnosed by a peptide vendor.